Edition:
United Kingdom

Glenmark Pharmaceuticals Ltd (GLEN.NS)

GLEN.NS on National Stock Exchange of India

644.95INR
7:41am GMT
Change (% chg)

Rs12.45 (+1.97%)
Prev Close
Rs632.50
Open
Rs632.50
Day's High
Rs644.95
Day's Low
Rs625.00
Volume
708,322
Avg. Vol
999,431
52-wk High
Rs972.95
52-wk Low
Rs525.85

Chart for

About

Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and... (more)

Overall

Beta: 0.27
Market Cap(Mil.): Rs172,813.91
Shares Outstanding(Mil.): 282.17
Dividend: 2.00
Yield (%): 0.33

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.62
EPS (TTM): -- -- --
ROI: -- 14.89 10.61
ROE: -- 16.37 14.21

BRIEF-Glenmark Pharma Gets Permission From CDSCO For Phase IIb Dose Range Finding Study For GRC 27864

* GETS PERMISSION BY CENTRAL DRUGS STANDARD CONTROL ORGANIZATION FOR PHASE IIB DOSE RANGE FINDING STUDY FOR GRC 27864 Source text - http://bit.ly/2mEqR6R Further company coverage:

15 Jan 2018

BRIEF-Glenmark Pharmaceuticals Launches Biosimilar Of Adalimumab In India

* LAUNCHES BIOSIMILAR OF ADALIMUMAB IN INDIA Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-Glenmark Pharmaceuticals Gets ANDA Approval For Norethindrone Acetate, Ethinyl Estradiol Tablets

* GETS ANDA APPROVAL FOR NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL TABLETS USP AND FERROUS FUMARATE TABLETS Source text - http://bit.ly/2BGPRjs Further company coverage:

27 Dec 2017

BRIEF-Glenmark Pharmaceuticals Meets Primary Clinical Endpoint In Phase 3 Study Of Ryaltris

* SAYS MET ITS PRIMARY CLINICAL ENDPOINT IN A PHASE 3 STUDY EVALUATING SAFETY OF RYALTRIS

14 Dec 2017

BRIEF-Glenmark Pharma Says Closed DCP For Generic Seretide Accuhaler In Nordic Region​

* ANNOUNCES CLOSURE OF DECENTRALISED REGISTRATION PROCEDURE (DCP) FOR GENERIC SERETIDE ACCUHALER IN NORDIC REGION​ Source text - http://bit.ly/2ByD8zw Further company coverage:

01 Dec 2017

BRIEF-Glenmark Pharma Says U.S. FDA issues 7 Form 483 observations for co's ‍Baddi Unit

* GLENMARK PHARMACEUTICALS SAYS ‍BADDI UNIT UNDERWENT AN U.S. FDA AUDIT FROM NOVEMBER 6, 2017 TO NOVEMBER 11, 2017

28 Nov 2017

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for HAILEY Fe 1/20 tablets ​

Nov 22 Glenmark Pharmaceuticals Ltd * Gets ANDA approval for HAILEY Fe 1/20 tablets ​ Source text - http://bit.ly/2hRulnp Further company coverage:

22 Nov 2017

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for Haileytm 24 FE 1 mg/20 mcg​

* Gets ANDA approval for Haileytm 24 fe 1 mg/20 mcg​ Source text for Eikon: Further company coverage:

20 Nov 2017

BRIEF-India's Glenmark Pharmaceuticals Sept-qtr consol profit falls about 4 pct

* Sept quarter consol profit 2.14 billion rupees versus profit of 2.24 billion rupees last year

02 Nov 2017

BRIEF-Glenmark Pharmaceuticals gets ANDA approval for aprepitant capsules USP​

* Says ‍Glenmark Pharmaceuticals receives ANDA approval for aprepitant capsules USP​ Source text - http://bit.ly/2gHsEFg Further company coverage:

16 Oct 2017

Earnings vs. Estimates